Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates HBsAg isoform kinetics predict treatment outcomes in CHD patients, suggesting better personalized therapy.
Introduction: CHD can be treated with either the entry inhibitor bulevirtide (BLV) or the immune modulator pegylated interferon alpha-2a (PEG-IFN). However, predicting treatment response remains uncertain. The composition of hepatitis B surface antigen (HBsAg), including large (L), middle (M), and small (S) forms, has been associated with HBsAg loss in hepatitis B virus (HBV) mono-infection and clinical outcomes were associated with higher MHBs% at baseline (BL) in HBV/HDV-coinfected patients.
No takes yet. Share an insight, caveat, or question.
Rodemerk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: